Compare BBDC & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBDC | IRWD |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 962.2M | 850.8M |
| IPO Year | 2007 | 2010 |
| Metric | BBDC | IRWD |
|---|---|---|
| Price | $8.95 | $4.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $9.67 | $3.68 |
| AVG Volume (30 Days) | 584.2K | ★ 2.8M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 11.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.96 | 0.18 |
| Revenue | $281,866,000.00 | ★ $338,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $37.22 |
| P/E Ratio | ★ $9.25 | $25.75 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.66 | $0.53 |
| 52 Week High | $10.85 | $5.78 |
| Indicator | BBDC | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 51.59 |
| Support Level | $8.79 | $4.42 |
| Resistance Level | $9.01 | $5.13 |
| Average True Range (ATR) | 0.14 | 0.35 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 24.56 | 27.91 |
Barings BDC Inc operates as a closed-end, non-diversified investment company and has elected to be treated as a business development company. The company's investment objective is to generate current income by investing directly in privately held middle-market companies to help these companies fund acquisitions, growth, or refinancing. Barings employs fundamental credit analysis and targets investments in businesses with low levels of cyclicality and operating risk relative to other businesses in this market segment. The holding size of each position will generally be dependent upon a number of factors including total facility size, pricing and structure, and the number of other lenders in the facility.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.